Safety and Efficacy of γδ T Cell Against Gastric Cancer
γδ T Cell Immunotherapy for Treatment of Gastric Cancer
Sponsor: Beijing Doing Biomedical Co., Ltd.
A PHASE1/PHASE2 clinical study on Gastric Cancer, this trial is ongoing. The trial is conducted by Beijing Doing Biomedical Co., Ltd. and has accumulated 9 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Jan 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
Status: Unknown Status → Not Yet Recruiting
▶ Show 4 earlier versions
-
Oct 2019 — Dec 2019 [monthly]
Unknown Status PHASE1_PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jun 2018 — Oct 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jan 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Doing Biomedical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .